A euploid result from PGT-A testing is the best result you can hope for from this type of embryo screening. It means the trophectoderm cells biopsied from your embryo showed 46 chromosomes, which matters because embryos with missing or extra chromosomes are less likely to keep developing. The trophectoderm is the outer layer of the blastocyst, which later helps form the placenta. So when your report says euploid, it is giving you reassuring chromosome information from the cells that were tested.
An aneuploid embryo has a chromosome number that is not 46. There may be an extra chromosome, a missing one, or both — across one pair or several.
Chromosomes carry the genetic instructions that guide every stage of development. When the number is wrong, those instructions are incomplete. The embryo may begin to divide, but in the vast majority of cases the development cannot continue. This is not a failure of the embryo in any other sense — not its appearance, not its development speed, not how it looked under the microscope. It is a chromosomal finding from the cells that were biopsied, and it is why aneuploid embryos are not recommended for transfer.
Aneuploidy is also more common than most women are told. In women aged 35–37 the aneuploidy rate across tested embryos is around 54% — rising to 63% at 38–40 and 66% at 41–42. PGT-A makes visible something that has always been happening. If your embryos came back aneuploid, that is a hard result to sit with. It is also the test doing exactly what it was designed to do. This is not a reflection of your body failing. It is the biology of human reproduction. PGT-A makes visible something that has always been happening. If your embryos came back aneuploid, that is a hard result to sit with. It is also the test doing exactly what it was designed to do.
Mosaic sits between euploid and aneuploid. The biopsy detected a mixture of chromosomally normal and abnormal signals in the same sample.
It does not mean the embryo is aneuploid. What it means depends on two things: how much of the sample was abnormal, and which chromosomes were involved. Not all chromosomes carry the same clinical significance. Some chromosome abnormalities are associated with more serious developmental consequences than others — certain chromosomes, if affected, are incompatible with development regardless of the proportion involved, while abnormalities on others may carry less clinical weight. Your clinic will read your mosaic result against both of these factors before any transfer decision is made.
Some mosaic embryos have been transferred and resulted in healthy pregnancies. The evidence on mosaic transfer outcomes shows results vary considerably by mosaicism level and chromosome type. A mosaic result is not a closed door. It is a result that needs your specific details, not a general category.
An inconclusive result means the laboratory could not produce a clear classification from the biopsy taken. It does not mean the embryo is abnormal.
The biopsy removes a small number of trophectoderm cells — typically five to eight. That sample then goes through a process of DNA amplification before analysis. If the sample fails to amplify sufficiently, or produces signals that fall below the threshold required for a confident classification, the result comes back inconclusive. The embryo itself has not been assessed. The sample has. Those are not the same thing.
Receiving an inconclusive result after waiting for your PGT-A report is its own particular difficulty. It does not close a door — but it does not open one cleanly either. Your clinic may discuss rebiopsy if the embryo is still viable and the grade supports it. In some cases, transfer may be considered on the basis of the embryo’s other characteristics. An inconclusive result is a laboratory outcome. It is not a verdict on the embryo.
These terms are not simply another word for aneuploid. They describe something more extensive.
An aneuploid result typically involves one chromosome pair — an extra copy, or a missing one. Chaotic and complex abnormal describe embryos where multiple chromosomes across multiple pairs are affected simultaneously. The disruption is not isolated. It is systemic. The chromosome picture has no coherent pattern from which development could reliably proceed.
Neither is recommended for transfer. If you see these terms on your report, they are telling you something specific about the scale of the chromosome disruption — not about you, not about your age, not about what is possible in a future cycle.
Your embryo grade and your PGT-A result are two separate assessments measuring different things.
Most clinics use the Gardner system. It grades a blastocyst across three criteria:
A 4AA describes an expanded blastocyst with strong organisation in both the inner cell mass and trophectoderm. A 3BB describes a slightly earlier stage with moderate cellular structure.
PGT-A tells you about chromosome number. A 4AA embryo can be aneuploid. A 3BB can be euploid.
Where both are read together is with mosaic embryos. Grade is one of the factors a clinic weighs when deciding whether a mosaic embryo is a transfer candidate — alongside mosaicism level and chromosome type.
Your PGT-A result and your embryo grade are both part of your clinic’s picture. Neither replaces the other. The chromosome result tells your clinic which embryos are candidates for transfer. The grade tells them how those embryos developed and how to handle them.
If you have a euploid embryo moving toward transfer, the chromosome checkpoint has been passed. Your clinic has what it needs to proceed. The question you have been carrying — is this embryo ready — has been answered. What you are asking now is different.
Having a tested embryo for transfer is an important milestone, but is not your final destination.
The next question is: is my body ready?
Research on single euploid blastocyst transfer puts live birth rates at around 62%. In reproductive medicine, that is a significant figure. It tells you something important: a chromosomally normal embryo, transferred into a prepared uterus, has real and meaningful odds.
It also tells you something else. There is a gap. And the gap is not about the embryo — your embryo has passed that screen. The gap is about everything that happens after transfer.
Implantation is not a single event. It is a biologically active phase — a precise window in which five distinct processes must unfold in sequence:
Each of those five processes has a specific nutritional demand. The fourteen days after transfer are when those demands are active. This is not a window where general healthy eating or supplements is enough.
The Now Baby FET Implantation Meal Plan is built around exactly that window. Every meal across the fourteen days has been designed around the nutritional demands of the implantation window — every process, every nutrient, every day — professionally analysed and structured so that the one variable that remains within your control is no longer left to chance.
You have optimised everything your clinic controls. This is the part only you can do.
A euploid result from PGT-A testing is the best result you can hope for from this type of embryo screening. It means the trophectoderm cells biopsied from your embryo showed 46 chromosomes, which matters because embryos with missing or extra chromosomes are less...
Your embryo transfer is approaching and now you may be doubting if you can successfully navigate the next phase. IVIG has been suggested — but is it really worth it. The Human Fertilisation and Embryology Authority has evaluated it for you.The Human...
When low AMH is diagnosed and your clinic wants to use donor eggs it can cause an immediate recoil. This is probably something you have never considered before. And before you make any decision, it is worth being clear on what your AMH result is actually...
Egg reserve is often spoken about as if it were a fixed store of eggs that can be counted, measured, and predicted.In reality, what we are trying to understand is ovarian activity — how many follicles are present, how many have left dormancy, and how many are actively...
You may have been told your NK cells are high. Your clinic has recommended intralipids — an intravenous fat infusion offered before transfer to calm the immune response that may, the theory goes, be working against your embryo. The test felt like an answer...
Your embryo is ready for transfer. And your clinic has suggested assisted hatching — a brief laboratory procedure performed on your embryo before it is placed in the uterus.The idea behind it is straightforward. Your embryo is surrounded by a protective...